Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412127 | 0.97 | MET (0.66) | METJAK2INPPL1ALKMAP4K2 | |
| Hydrochloric Acid SCHEMBL2840129 | 0.96 | MET (0.65) | METJAK2INPPL1ALKMAP4K2 | |
| Hydrochloric Acid SCHEMBL2840128 | 0.95 | MET (0.65) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL30453504 | 0.92 | MET (0.75) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL488666 | 0.92 | MET (0.75) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL5252099 | 0.88 | MET (0.80) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL30452860 | 0.88 | MET (0.80) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL3113354 | 0.88 | MET (0.80) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL488694 | 0.88 | MET (0.80) | METJAK2INPPL1ALKMAP4K2 | |
| SCHEMBL13412111 | 0.88 | MET (0.65) | METALKMAP4K2MAP3K1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | claimed |
| EP-2120578-A1 | KINASE INHIBITOR COMPOUNDS | Xcovery, INC. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008088881-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | MAP4K2, MAP3K5, MAP3K15 | MET 1412/4885JAK2 403/4885INPPL1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.